key: cord-0724198-qmqocq34 authors: Bi, Xiaojie; Liu, Wei; Ding, Xuan; Liang, Shuang; Zheng, Yufen; Zhu, Xiaoli; Quan, Sheng; Yi, Xiao; Xiang, Nan; Du, Juping; Lyu, Haiyan; Yu, Die; Zhang, Chao; Xu, Luang; Ge, Weigang; Zhan, Xinke; He, Jiale; Xiong, Zi; Zhang, Shun; Li, Yanchang; Xu, Ping; Zhu, Guangjun; Wang, Donglian; Zhu, Hongguo; Chen, Shiyong; Li, Jun; Zhao, Haihong; Zhu, Yi; Liu, Huafen; Xu, Jiaqin; Shen, Bo; Guo, Tiannan title: Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19 date: 2021-12-28 journal: Cell Rep DOI: 10.1016/j.celrep.2021.110271 sha: 02810e43e27d8c1eeeef4b179fc82dcd3bf8e14b doc_id: 724198 cord_uid: qmqocq34 The utility of the urinary proteome in infectious diseases remains unclear. Here we analyzed the proteome and metabolome of urine and serum samples from patients with COVID-19 and healthy controls. Our data show that urinary proteins effectively classify COVID-19 by severity. We detect 197 cytokines and their receptors in urine but only 124 in serum using TMT-based proteomics. Decrease of urinary ESCRT complex proteins correlates with active SARS-CoV-2 replication. Downregulation of urinary CXCL14 in severe COVID-19 cases positively correlates with blood lymphocyte counts. Integrative multiomic analysis suggests that innate immune activation and inflammation triggered renal injuries in patients with COVID-19. COVID-19-associated modulation of the urinary proteome offers unique insights into the pathogenesis of this disease. This study demonstrates the added value of including the urinary proteome in a suite of multiomic analytes in evaluating the immune pathobiology and clinical course of COVID-19 and, potentially, other infectious diseases. CCL 25 CX CL 14 P P B P C X C L 1 2 C X 3 C L 1 C C L 1 4 C X C L 1 6 C C L 1 6 P F 4 C C L 5 C C L 1 8 C C L 1 5 IL 1 R N IL 1 8 IL 3 4 GD F1 5 TG FB 1 T N F S F 1 3 T N F S F 8 T N F S F 1 3 B cases with flu-like symptoms such as cough and fever, and 27 healthy 108 controls were enrolled as controls ( Figure 1A ; Table 1; Table S1 ). Age and (Table S1 ; Figure S1A , B, C). In addition, 106 urine samples (Table 116 S1; Figure S1C ). Peptide yields from serum samples were not significantly different among 118 the four groups (healthy, non-COVID-19, non-severe, and severe), indicating 119 reproducibility of our sample preparation method ( Figure 1B ). However, 120 peptide yields from urine specimens were significantly higher in severe and 121 non-severe cases than from healthy controls ( Figure 1B ). This observation 122 confirms a report of proteinuria in patients infected with SARS-CoV-2 (Su et 123 al., 2020). 124 We identified and quantified 16,148 peptides and 1494 proteins from sera 125 using TMT-based proteomics, while 19,732 peptides and 3854 proteins were 126 identified from urine using similar methodology (Methods , Table S2 ; Figure 127 1C, D). The proteomic depth of urine specimens achieved in this study 128 exceeds most other published studies (Table S3) , and is reasonably deep to 129 encompass most urinary proteins. Moreover, we characterized 1033 urine 130 metabolites and 903 serum metabolites in patients with COVID-19 (Table S2; 131 Figure 1E ). The serum and urine proteome data set showed minimal batch 132 effects ( Figure S1D , E). The median coefficients of variance (CV) of the 133 quality control (QC) samples were 13% for proteomic data and 3.5% for 134 metabolomic data, indicating robust quality of our data ( Figure 1F ). showed that the numbers of quantified metabolites in sera and urine are 143 similar ( Figure 1E , 903 vs.1033). Unlike proteins however, 62% of serum 144 metabolites, i.e. 557 metabolites, were detectable in urine ( Figure 1E ). The 145 discrepancy in protein and metabolite detection is probably due to differences 146 in their abundance and stability in sera and urine. It is generally assumed that the molecular weight (MW) cutoff for structure organization related to biological processes ( Figure 2D ). We further 183 explored the power for classifying severity of these top 20 urinary proteins 184 compared to that for sera. By increasing the number of proteins in the model, 185 we optimized 20 random forest models for each specimen type and evaluated 186 the performance of the respective classifier in terms of accuracy and area 187 under curve (AUC) after internal cross-validation, as detailed in Methods. Our 188 data showed that urine-derived models performed equally well as those from 189 sera ( Figure 2E ). As the number of features in the model exceeded the top 190 four, the accuracy of the models for both sample types rose beyond 0.9, and 191 the AUC was higher than 0.95 ( Figure 2E ). To further evaluate the performance of such urinary proteins for 193 classifying COVID-19 severity, we trained a model using the 20 urinary 194 proteins above and tested it on an independent TMT-labelled urinary 195 proteomic data set of 13 patients with COVID-19 (Table S2) Figure 2F ). These data further support the utility of our urinary protein model 205 for predicting progression to clinical severity in early infection. Taken together, our data showed that urinary proteomics can be as 207 informative as that of sera in terms of classifying and predicting COVID-19 208 severity. Considering its non-invasive nature and easy accessibility, urine 209 could be a widely used sample source for COVID-19 management. Nevertheless, more independent validation is required before this could 211 become clinical standard of care. Cytokines produced by immune cells mediate diverse immune processes. Table S4 ). The dysregulated proteins in serum were enriched in 23 pathways and 323 those in urine in 108 pathways. Interestingly, 20 pathways from the serum 324 data also appeared in the urine data ( Figure 4C ; Table S5 ), suggesting that 364 The dysregulated metabolites in COVID-19 urine and serum were 365 enriched in ten KEGG pathways (Table S5) , including tryptophan biosynthesis 366 and metabolism ( Figure 4E ; Table S5 ). There are three metabolic pathways produce more quinolinate after an inflammatory response (Heyes, 1993) . Taken as a whole, the metabolomic data point to widely activated ROS 406 production which could lead to a variety of immune-mediated tissue injury in 407 patients with COVID-19. Inflammation induced renal injuries as revealed by multiomics data 409 The 20 pathways prominent in both serum and urine were mainly related 410 to immunity (Table S6) . We found most immunity related pathways were 411 downregulated in urine but upregulated in serum, except for protein kinase A 412 signaling, coagulation system, acute phase response signaling, and LXR/RXR 413 activation, which were upregulated in both serum and urine (Table S6) . Protein kinase A signaling was reported to be involved in the innate immunity (Table S5) , the 427 leukocyte extravasation signaling pathway stood out for its activation level (Z 428 score 2.6) ( Figure 5A ; Table S5 ). Vascular cell adhesion protein 1 (VCAM-1) 429 and intercellular adhesion molecule 1 (ICAM-1), which participate in leukocyte Figure S1I , Figure S2H and Figure S6B ). LRP2 and CDC42 also 514 showed a declining trend, though not statistically significant. ELISA showed 515 similar results, but did not achieve statistical significance ( Figure S1I ). This 516 may be because ELISA is an antibody-based chromogenic reaction whose 517 performance is crucially dependent on antibody quality (sensitivity and In this study, about 35% non-COVID-19 cases and 37% patients with 533 COVID-19 had comorbidities such as hypertension and diabetes (Table 1) . 534 We cannot completely exclude effects of comorbidities on changes in the 535 proteomic or metabolomic data. However, we took care to ensure that COVID- In this study, patients scored as 3 or 4 were defined as non-severe patients, 689 and patients scored as score 5 or 6 were defined as severe patients (Table 690 S1 ). We also included 17 non-COVID-19 cases, who had clinical symptoms 691 similar to COVID-19, including fever and/or cough, but the nucleic acid test antibiotics (Table 1) . The fasting venous blood and the first-morning midstream urine of all 701 subjects were collected in the morning. The venous blood samples were 1% target false discovery rate (FDR). The protein abundance ratios of target samples to the pooled sample 818 within each batch were used as the relative protein abundance for data 819 analysis. For metabolomics data analysis, metabolites were identified by searching 821 an in-house library of more than 3,300 standards whose data entries are Mfuzz analysis, we selected 148 DEPs in clusters 1, 2, 3 and 4 ( Figure S4B ) 873 and 161 DEMs in cluster 1, 3, 6 and 7 ( Figure S4D ) for further pathway 874 enrichment analysis. For urine, we selected 580 DEPs in clusters 1, 3, 5, 6 875 and 7 ( Figure S4C ) and 138 DEMs in clusters 2, 6 and 8 for further pathway 876 enrichment analysis ( Figure S4E ). Machine learning 879 An R package RandomForest (version 4.6.14) was used to select SHH CR2 AGT MRC1 RNASE4 IGFBP2 ALB IL6R VSIG4 TKT IL1R2 IGFBP3 LEAP2 VWF SERPINA3 F9 APMAP FBLN5 SAA1 IGF1 5 7 9 11 MeanDecreaseAccuracy Top 20 features in serum Top 20 features in urine BTNL3 CD84 SPOCK1 RHDE CDH19 CDH22 MADCAM1 SERPINI1 PRSS2 MELTF NPR3 ICOSLG OSTN ADGRL1 MLEC PTGFRN TNR FREM2 CEL VPS36 5 6 7 8 MeanDecreaseAccuracy SAA1 IL6R SERPINA3 TKT VWF MRC1 APMAP IL1R2 AGT F9 LEAP2 RNASE4 IGFBP2 FBLN5 VSIG4 ALB SHH CR2 IGFBP3 SERPINI1 CDH19 ICOSLG TRHDE NPR3 FREM2 PTGFRN ADGRL1 CEL MADCAM1 SPOCK1 MELTF VPS36 BTNL3 CDH22 CD84 OSTN TNR CCL2 5 CX CL 14 P P B P C X C L 1 2 C X 3 C L 1 C C L 1 4 C X C L 1 6 C C L 1 6 P F 4 C C L 5 C C L 1 8 E TSG101 VPS28 VPS37D VPS36 SNF8 VPS25 CHMP2A CHMP3 CHMP4A CHMP4B CHMP4C CHMP5 CHMP1B LRSAM1 VPS4A VPS4B PDCD6IP VTA1 Group Sex Age TSG101 VPS28 VPS37D VPS25 CHMP2A CHMP3 CHMP4A CHMP4B CHMP4C CHMP5 CHMP1B LRSAM1 VPS4A VPS4B PDCD6IP Highlights  More cytokines and their receptors are detected in urine than in serum  Machine learning models based on urinary proteins equal the ones using sera proteins  Dysregulated inflammatory processes induce renal injury as revealed by multiomics data The value of the urine proteome is largely underestimated compared to the blood proteome. Bi et al. systematically compare proteins and metabolites in COVID-19 urine and sera, and show the urine proteome to be a valuable source of biomarkers, offering unique insights into the pathogenesis of infectious diseases. The human urinary Coronavirus and PARP 1007 expression dysregulate the NAD Metabolome: a potentially actionable component of 1008 innate immunity Quinolinic acid and inflammation Membrane budding and scission by the ESCRT 1012 machinery: it's all in the neck Podocyte energy metabolism and glomerular 1014 diseases Gene Summary An update of urine and blood metabolomics in 1017 chronic kidney disease Evaluation of Coronavirus 1020 Disease 2019 Severity Using Urine Biomarkers Causal analysis 1022 approaches in Ingenuity Pathway Analysis Plasma and urinary 1026 levels of adrenomedullin in chronic glomerulonephritis patients with proteinuria Mfuzz: a software package for soft clustering 1029 of microarray data The seven amino acids of human RAMP2 (86) and RAMP3 (59) are 1032 critical for agonist binding to human adrenomedullin receptors Immune-centric network of cytokines and cells in disease context identified by 1037 computational mining of PubMed Taurine and hypotaurine content 1039 of human leukocytes Sphingosine-1-phosphate reduces hepatic ischaemia/reperfusion-induced acute 1042 kidney injury through attenuation of endothelial injury in mice Inflammation and coagulation Urinary epidermal growth factor as a prognostic marker 1048 for the progression of Alport syndrome in children Urine proteome of COVID-19 patients Quinolinic Acid: An Endogenous Neurotoxin with Multiple 1055 The beneficial role of retinoids in glomerular 1057 disease Taurine and inflammatory diseases UMAP: Uniform Manifold Approximation 1061 and Projection for Dimension Reduction Clinical Proteomics Reveals Classifiers of COVID-19 Infection Urinary cAMP activity in chronic renal 1067 failure Getting leukocytes to the site of inflammation Advancing Urinary Protein Biomarker Discovery by Data-Independent 1072 Orbitrap Mass Spectrometer Urinary megalin deficiency 1076 implicates abnormal tubular endocytic function in Fanconi syndrome COVID-19 infection and oxidative stress: an under-explored Podocyte-actin dynamics 1092 in health and disease Dysregulation of immune response in patients with 1095 COVID-19 in Wuhan, China Networking Rho family GTPases in lymphocytes Acute kidney injury The value of urine biochemical parameters in the prediction 1102 of the severity of coronavirus disease 2019 Podocyte RhoGTPases: new therapeutic targets 1105 for nephrotic syndrome? Rho-GTPases as key regulators 1107 of T lymphocyte biology Expression of interleukin 6 in the rat striatum following stereotaxic 1110 injection of quinolinic acid Coagulation factor V and 1116 thrombophilia: background and mechanisms Proteomic and Metabolomic Characterization of COVID-19 Inhibition of TGF-β1-receptor posttranslational core fucosylation 1122 attenuates rat renal interstitial fibrosis N-Acetylcysteine to Combat COVID-19: An Evidence 1124 The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase 1130 complex to control autophagy Renal histopathological analysis of 26 postmortem 1134 findings of patients with COVID-19 in China Links between coagulation, 1137 inflammation, regeneration, and fibrosis in kidney pathology Lymphopenia predicts disease severity of COVID-19: a descriptive and 1141 predictive study COVID-19 1144 infection results in alterations of the kynurenine pathway and fatty acid metabolism 1145 that correlate with IL-6 levels and renal status Immune suppression in the early stage of COVID-19 disease Urinary proteome profiling for 1152 stratifying patients with familial Parkinson's disease Urinary cyclic AMP and post-traumatic acute renal failure Characterizing 1159 Patients with Recurrent Urinary Tract Infections in Vesicoureteral Reflux: A Pilot 1160 Study of the Urinary Proteome Chorionic gonadotropin can enhance innate immunity by 1164 stimulating macrophage function Report of the WHO-China Joint Mission on Coronavirus Disease Coronavirus Updates Ephrins and Eph Receptor 1171 Signaling in Tissue Repair and Fibrosis